Role of scavenger receptors in the pathophysiology of chronic liver diseases

Critical Reviews in Immunology

Volumn 33, Issue 1, 2013, Pages 57-96

  Armengol, Carolina ^a,b   Bartolí, Ramon ^b,c   Sanjurjo, Lucía ^d   Serra, Isabel ^a   Amézaga, Núria ^d   Sala, Margarita ^e   Sarrias, Maria Rosa ^d  

^a Germans Trias i Pujol Research Institute in Health Sciences   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Experimental Cirrhosis Group (IGTP)   (Spain)

^d Innate Immunity Health Sciences Research Institute Germans Trias i Pujol   (Spain)

^e HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Cirrhosis; Fibrosis; Hepatocellular carcinoma; Innate immunity

Indexed keywords

BIOLOGICAL MARKER; CD163 ANTIGEN; CD36 ANTIGEN; CD5 ANTIGEN; DELETED IN MALIGNANT BRAIN TUMOR 1 PROTEIN; DNA; FATTY ACID; GLYCOPROTEIN; LIPOPOLYSACCHARIDE; LIPOTEICHOIC ACID; MAC 2 BINDING PROTEIN; MEMBRANE PROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; SCAVENGER RECEPTOR; SCAVENGER RECEPTOR A; SCAVENGER RECEPTOR A MEMBER 5; SCAVENGER RECEPTOR BI; SCAVENGER RECEPTOR EXPRESSED BY ENDOTHELIAL CELL 1; SOLUBLE PROTEIN ALPHA; TOLL LIKE RECEPTOR; TOXIN; UNCLASSIFIED DRUG;

ALCOHOL ABUSE; BONE MARROW CELL; CHRONIC INFLAMMATION; CHRONIC LIVER DISEASE; CROSS PRESENTATION; DENDRITIC CELL; ENDOTHELIUM CELL; EPITHELIUM CELL; FATTY LIVER; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HOMEOSTASIS; HUMAN; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; KUPFFER CELL; LIPID LIVER LEVEL; LIPID TRANSPORT; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; MACROPHAGE ACTIVATION; METABOLIC DISORDER; MORBIDITY; MORTALITY; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOPHYSIOLOGY; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; STELLATE CELL; T LYMPHOCYTE; VIRUS ENTRY;

EID: 84876008152     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: 10.1615/critrevimmunol.2013006794     Document Type: Review

References (351)

1. Ishibashi H, Nakamura M, Komori A, Migita K, Shimoda S. Liver architecture, cell function, and disease. Semin Immunopathol. 2009 Sep;31(3):399-409.
2. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005 Feb;115(2):209-18.
3. Mendez-Sanchez N, Villa AR, Zamora-Valdes D, Morales-Espinosa D, Uribe M. Worldwide mortality from cirrhosis. Ann Hepatol. 2007 Jul-Sep;6(3):194-5.
4. Thio CL, Thomas DL, Carrington M. Chronic viral hepatitis and the human genome. Hepatology. 2000 Apr;31(4):819-27.
5. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012 May;142(6):1264-73.
6. Guicciardi ME, Gores GJ. Apoptosis: a mechanism of acute and chronic liver injury. Gut. 2005 Jul;54(7):1024-33.
7. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science. 2011 Jun 24;332(6037):1519-23.
8. Ludwig J, McGill DB, Lindor KD. Review: nonalcoholic steatohepatitis. J Gastroenterol Hepatol. 1997 May;12(5):398-403.
9. Lieber CS. Alcoholic liver disease: new insights in pathogenesis lead to new treatments. J Hepatol. 2000;32(1 Suppl):113-28.
10. Mann RE, Smart RG, Govoni R. The epidemiology of alcoholic liver disease. Alcohol Res Health. 2003;27(3):209-19.
11. Purohit V, Gao B, Song BJ. Molecular mechanisms of alcoholic fatty liver. Alcohol Clin Exp Res. 2009 Feb;33(2):191-205.
12. Ajakaiye M, Jacob A, Wu R, Nicastro JM, Coppa GF, Wang P. Alcohol and hepatocyte-Kupffer cell interaction (review). Mol Med Report. 2011 Jul-Aug;4(4):597-602.
13. Feldman M, Friedman L, Brandt L. Sleisenger and Fordtran's gastrointestinal and liver disease. 9th ed. Philadelphia, PA, USA: Ed Saunders; 2010.
14. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008 Mar 8;371(9615):838-51.
15. Pardo A, Bartolí R, Lorenzo-Zúñiga V, Planas R, Viñado B, Riba J, Cabré E, Santos J, Luque T, Ausina V, Gassull MA. Effect of cisapride on intestinal bacterial overgrowth and bacterial translocation in cirrhosis. Hepatology. 2000 Apr;31(4):858-63.
16. Llovet JM, Bartolí R, Planas R, Cabré E, Jimenez M, Urban A, Ojanguren I, Arnal J, Gassull MA. Bacterial translocation in cirrhotic rats. Its role in the development of spontaneous bacterial peritonitis. Gut. 1994 Nov;35(11):1648-52.
17. Jung KS, Kim SU, Ahn SH, Park YN, Kim do Y, Park JY, Chon CY, Choi EH, Han KH. Risk assessment of hepatitis B virus-related hepatocel-lular carcinoma development using liver stiffness measurement (FibroScan). Hepatology. 2011 Mar;53(3):885-94.
18. Ripoll C, Groszmann RJ, Garcia-Tsao G, Bosch J, Grace N, Burroughs A, Planas R, Escorsell A, Garcia-Pagan JC, Makuch R, Patch D, Matloff DS; Portal Hypertension Collaborative Group. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol. 2009 May;50(5):923-8.
19. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004 Nov;127(5 Suppl 1):S5-16.
20. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010 Dec 15;127(12):2893-917.
21. Bruix J, Sherman M. Management of hepatocel-lular carcinoma: an update. Hepatology. 2011 Mar;53(3):1020-2.
22. Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis. 2010 Feb;30(1):3-16.
23. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012 Apr;56(4):908-43.
24. Elsharkawy AM, Mann DA. Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis. Hepatology. 2007 Aug;46(2):590-7.
25. Zhang DY, Friedman SL. Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology. 2012 Aug;56(2):769-75.
26. Armengol C, Boix L, Bachs O, Solé M, Fuster J, Sala M, Llovet JM, Rodés J, Bruix J. p27(Kip1) is an independent predictor of recurrence after surgi-cal resection in patients with small hepatocellular carcinoma. J Hepatol. 2003 May;38(5):591-7.
27. El-Serag HB, Lechel A, Rudolph KL. Epidemiology and molecular mechanisms of hepatocarcinogenesis. Boyer TD, Manns MP, Sanyal AJ, editors. New York: Elsevier; 2010.
28. Pogribny I P, Rusyn I. Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma. Cancer Lett. 2012 Feb 2. [Epub ahead of print] edpub 2012.
29. Thorgeirsson SS, Grisham JW. Molecular patho-genesis of human hepatocellular carcinoma. Nat Genet. 2002 Aug;31(4):339-46.
30. Boyault S, Rickman DS, de Reyniès A, Balabaud C, Rebouissou S, Jeannot E, Hérault A, Saric J, Belghiti J, Franco D, Bioulac-Sage P, Laurent-Puig P, Zucman-Rossi J. Transcriptome clas-sification of HCC is related to gene alterations and to new therapeutic targets. Hepatology. 2007 Jan;45(1):42-52.
31. Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, Chiang DY, Villanueva A, Newell P, Ikeda K, Hashimoto M, Watanabe G, Gabriel S, Friedman SL, Kumada H, Llovet JM, Golub TR. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 2009 Sep 15;69(18):7385-92.
32. Cairo S, Armengol C, De Reyniès A, Wei Y, Thomas E, Renard CA, Goga A, Balakrishnan A, Semeraro M, Gresh L, Pontoglio M, StrickMarchand H, Levillayer F, Nouet Y, Rickman D, Gauthier F, Branchereau S, Brugières L, Laithier V, Bouvier R, Boman F, Basso G, Michiels JF, Hofman P, Arbez-Gindre F, Jouan H, Rousselet-Chapeau MC, Berrebi D, Marcellin L, Plenat F, Zachar D, Joubert M, Selves J, Pasquier D, Bioulac-Sage P, Grotzer M, Childs M, Fabre M, Buendia MA. Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell. 2008 Dec 9;14(6):471-84.
33. Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF, Mikaelyan A, Roberts LR, Demetris AJ, Sun Z, Nevens F, Roskams T, Thorgeirsson SS. A novel prognostic subtype of human hepatocel-lular carcinoma derived from hepatic progenitor cells. Nat Med. 2006 Apr;12(4):410-6.
34. Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H, Budhu A, Zanetti KA, Chen Y, Qin LX, Tang ZY, Wang XW. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 2008 Mar 1;68(5):1451-61.
35. Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D, Alsinet C, Cornella H, Liberzon A, Kobayashi M, Kumada H, Thung SN, Bruix J, Newell P, April C, Fan JB, Roayaie S, Mazzaferro V, Schwartz ME, Llovet JM. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology. 2011 May;140(5):1501-12.
36. Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem. 1983;52:223-61.
37. Areschoug T, Gordon S. Scavenger receptors: role in innate immunity and microbial pathogenesis. Cell Microbiol. 2009;11(8):1160-9.
38. Murphy JE, Tedbury PR, Homer-Vanniasinkam S, Walker JH, Ponnambalam S. Biochemistry and cell biology of mammalian scavenger receptors. Atherosclerosis. 2005 Sep;182(1):1-15.
39. Freeman M, Ashkenas J, Rees DJ, Kingsley DM, Copeland NG, Jenkins NA, Krieger M. An ancient, highly conserved family of cysteine-rich protein domains revealed by cloning type I and type II murine macrophage scavenger receptors. Proc Natl Acad Sci U S A. 1990 Nov;87(22):8810-4.
40. Sarrias MR, Gronlund J, Padilla O, Madsen J, Holmskov U, Lozano F. The Scavenger Receptor Cysteine-Rich (SRCR) domain: an ancient and highly conserved protein module of the innate immune system. Crit Rev Immunol. 2004;24(1):1-37.
41. Acton SL, Scherer PE, Lodish HF, Krieger M. Expression cloning of SR-BI, a CD36-related class B scavenger receptor. J Biol Chem. 1994;269(33):21003-9.
42. Calvo D, Vega MA. Identification, primary structure, and distribution of CLA-1, a novel member of the CD36/LIMPII gene family. J Biol Chem. 1993 Sept;268(25):18929-35.
43. Swarnakar S, Temel RE, Connelly MA, Azhar S, Williams DL. Scavenger receptor class B, type I, mediates selective uptake of low density lipoprotein cholesteryl ester. J Biol Chem. 1999 Oct 15;274(42):29733-9.
44. Stangl H, Hyatt M, Hobbs HH. Transport of Lipids from High and Low Density Lipoproteins via Scavenger Receptor-BI. J Biol Chem. 1999 Nov 12;274(46):32692-8.
45. Burlone ME, Budkowska A. Hepatitis C virus cell entry: role of lipoproteins and cellular receptors. J Gen Virol. 2009 May 1;90(5):1055-70.
46. Baumert TF, Vergalla J, Satoi J, Thomson M, Lechmann M, Herion D, Greenberg HB, Ito S, Liang TJ. Hepatitis C virus-like particles synthesized in insect cells as a potential vaccine candidate. Gastroenterology. 1999 Dec;117(6):1397-407.
47. Bartosch B, Dubuisson J, Cosset Fo-Lc. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med. 2003 Mar 3;197(5):633-42.
48. Lindenbach BD, Evans MJ, Syder AJ, Wölk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM. Complete replication of hepatitis C virus in cell culture. Science. 2005 Jul 22;309(5734):623-6.
49. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Kräusslich HG, Mizokami M, Bartenschlager R, Liang TJ. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med. 2005;11(7):791-6.
50. Zeisel MB, Fofana I, Fafi-Kremer S, Baumert TF. Hepatitis C virus entry into hepatocytes: Molecular mechanisms and targets for antiviral therapies. J Hepatol. 2011;54(3):566-76.
51. Dorner M, Horwitz JA, Robbins JB, Barry W T, Feng Q, Mu K, Jones CT, Schoggins JW, Catanese MT, Burton DR, Law M, Rice CM, Ploss A. A genetically humanized mouse model for hepatitis C virus infection. Nature. 2011;474(7350):208-11.
52. Barth H, Schnober EK, Zhang F, Linhardt RJ, Depla E, Boson B, Cosset FL, Patel AH, Blum HE, Baumert TF. Viral and cellular determinants of the hepatitis C Virus envelope-heparan sulfate interaction. J Virol. 2006 Nov 1;80(21):10579-90.
53. Germi R, Crance JM, Garin D, Guimet J, Lortat-Jacob H, Ruigrok RW, Zarski JP, Drouet E. Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption. J Med Virol. 2002;68(2):206-15.
54. Agnello V, Ãbel G, Elfahal M, Knight GB, Zhang Q-X. Hepatitis C virus and other Flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A. 1999;96(22):12766-71.
55. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D, Grandi G, Abrignani S. Binding of Hepatitis C Virus to CD81. Science. 1998 Oct 30;282(5390):938-41.
56. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, Traboni C, Nicosia A, Cortese R, Vitelli A. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 2002 Oct 1;21(19):5017-25.
57. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wölk B, Hatziioannou T, McKeating JA, Bieniasz PD, Rice CM. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature. 2007;446(7137):801-5.
58. Liu S, Yang W, Shen L, Turner JR, Coyne CB, Wang T. Tight junction proteins Claudin-1 and Occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J Virol. 2009 Feb 15;83(4):2011-4.
59. Bartosch B, Verney G, Dreux M, Donot P, Morice Y, Penin F, Pawlotsky JM, Lavillette D, Cosset FL. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and High-density lipo-protein promotes both enhancement of infection and protection against neutralizing antibodies. J Virol. 2005 Jul;79(13):8217-29.
60. Catanese MT, Graziani R, von Hahn T, Moreau M, Huby T, Paonessa G, Santini C, Luzzago A, Rice CM, Cortese R, Vitelli A, Nicosia A. High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. J Virol. 2007 Aug;81(15):8063-71.
61. Catanese MT, Ansuini H, Graziani R, Huby T, Moreau M, Ball JK, Paonessa G, Rice CM, Cortese R, Vitelli A, Nicosia A. Role of Scavenger Receptor Class B Type I in Hepatitis C Virus Entry: Kinetics and Molecular Determinants. J Virology. 2010 January 1;84(1):34-43.
62. Voisset Cc, Callens N, Blanchard E, Op De Beeck A, Dubuisson J, Vu-Dac N. High Density Lipoproteins Facilitate Hepatitis C Virus Entry through the Scavenger Receptor Class B Type I. J Biol Chem. 2005 Mar 4;280(9):7793-9.
63. von Hahn T, Lindenbach BD, Boullier A, Quehenberger O, Paulson M, Rice CM, McKeating JA. Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells. Hepatology. 2006;43(5):932-42.
64. Maillard P, Huby T, Andréo U, Moreau M, Chapman J, Budkowska A. The interaction of natural hepatitis C virus with human scavenger receptor SR-BI/Cla1 is mediated by ApoB-containing lipoproteins. FASEB J. 2006 Apr;20(6):735-7.
65. Dreux M, Dao Thi VL, Fresquet J, Guérin M, Julia Z, Verney G, Durantel D, Zoulim F, Lavillette D, Cosset FL, Bartosch B. Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domains. PLoS Pathog. 2009;5(2):e1000310.
66. Murao K, Imachi H, Yu X, Cao WM, Nishiuchi T, Chen K, Li J, Ahmed RA, Wong NC, Ishida T. Interferon alpha decreases expression of human scavenger receptor class BI, a possible HCV receptor in hepatocytes. Gut. 2008 May;57(5):664-71
67. Sarhan MA, Pham TNQ, Chen AY, Michalak TI. Hepatitis C virus infection of human T lymphocytes is mediated by CD5. J Virol. 2012 Apr 1;86(7):3723-35.
68. Jones NH, Clabby ML, Dialynas DP, Huang HJ, Herzenberg LA, Strominger JL. Isolation of complementary DNA clones encoding the human lymphocyte glycoprotein T1/Leu-1. Nature. 1986 Sep 25-Oct 1;323(6086):346-9.
69. Lankester AC, van Schijndel GM, Cordell JL, van Noesel CJ, van Lier RA. CD5 is associated with the human B cell antigen receptor complex. Eur J Immunol. 1994 Apr;24(4):812-6.
70. Osman N, Ley SC, Crumpton MJ. Evidence for an association between the T cell receptor/ CD3 antigen complex and the CD5 antigen in human T lymphocytes. Eur J Immunol. 1992 Nov;22(11):2995-3000.
71. Toyo-oka K, Yashiro-Ohtani Y, Park CS, Tai XG, Miyake K, Hamaoka T, Fujiwara H. Association of a tetraspanin CD9 with CD5 on the T cell surface: role of particular transmembrane domains in the association. Int Immunol. 1999 Dec;11(12):2043-52.
72. Carmo AM, Castro MA, Arosa FA. CD2 and CD3 associate independently with CD5 and differ-entially regulate signaling through CD5 in Jurkat T cells. J Immunol. 1999 Oct 15;163(8):4238-45.
73. Beyers AD, Spruyt LL, Williams AF. Molecular associations between the T-lymphocyte antigen receptor complex and the surface antigens CD2, CD4, or CD8 and CD5. Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2945-9.
74. Brossard C, Semichon M, Trautmann A, Bismuth G. CD5 inhibits signaling at the immunologi-cal synapse without impairing its formation. J Immunol. 2003 May 1;170(9):4623-9.
75. Hippen KL, Tze LE, Behrens TW. CD5 maintains tolerance in anergic B cells. J Exp Med. 2000 Mar 6;191(5):883-90.
76. Hawiger D, Masilamani RF, Bettelli E, Kuchroo VK, Nussenzweig MC. Immunological unrespon-siveness characterized by increased expression of CD5 on peripheral T cells induced by dendritic cells in vivo. Immunity. 2004 Jun;20(6):695-705.
77. Dalloul A. CD5: a safeguard against autoimmunity and a shield for cancer cells. Autoimmun Rev. 2009 Feb;8(4):349-53
78. Friedlein G, El Hage F, Vergnon I, Richon C, Saulnier P, Lécluse Y, Caignard A, Boumsell L, Bismuth G, Chouaib S, Mami-Chouaib F. Human CD5 protects circulating tumor antigen-specific CTL from tumor-mediated activation-induced cell death. J Immunol. 2007 Jun 1;178(11):6821-7.
79. Vera J, Fenutría R, Cañadas O, Figueras M, Mota R, Sarrias MR, Williams DL, Casals C, Yelamos J, Lozano F. The CD5 ectodomain interacts with conserved fungal cell wall components and protects from zymosan-induced septic shock-like syndrome. Proc Natl Acad Sci U S A. 2009 Feb 3;106(5):1506-11.
80. Blackard J T, Hiasa Y, Smeaton L, Jamieson DJ, Rodriguez I, Mayer KH, Chung RT. Compartmentalization of Hepatitis C Virus (HCV) during HCV/HIV Coinfection. J Infectious Diseases. 2007 June;195(12):1765-73.
81. Blackard J T, Ma G, Welge JA, Martin CM, Sherman KE, Taylor LE, Mayer KH, Jamieson DJ. Analysis of a non-structural gene reveals evidence of possible hepatitis C virus (HCV) compart-mentalization. J Med Virol. 2012;84(2):242-52.
82. Di Liberto G, Roque-Afonso AM, Kara R, Ducoulombier D, Fallot G, Samuel D, Feray C. Clinical and therapeutic implications of hepatitis C virus compartmentalization. Gastroenterology. 2006 Jul;131(1):76-84.
83. Durand T, Di Liberto G, Colman H, Cammas A, Boni S, Marcellin P, Cahour A, Vagner S, Féray C. Occult infection of peripheral B cells by hepatitis C variants which have low translational efficiency in cultured hepatocytes. Gut. 2010 Jul;59(7):934-42.
84. Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma: systematic review and meta-analysis. Gastroenterology. 2003 Dec;125(6):1723-32.
85. Lerat H, Berby F, Trabaud MA, Vidalin O, Major M, Trépo C, Inchauspé G. Specific detection of hepatitis C virus minus strand RNA in hematopoietic cells. J Clin Invest. 1996 Feb 1;97(3):845-51.
86. Kanamori H, Aburatani H, Takaku F, Suzuki H, Kobari Y, Miyai T, Takahashi K, Cohen EH, Wydro R, Housman DE, Kodama T. Human macrophage scavenger receptors: primary structure, expression, and localization in atherosclerotic lesions. Proc Natl Acad Sci U S A. 1990 Dec;87(23):9133-7.
87. Emi M, Asaoka H, Matsumoto A, Itakura H, Kurihara Y, Wada Y, Kanamori H, Yazaki Y, Takahashi E, Lepert M, Lalouel JM, Kodama T, Mukai T. Structure, organization, and chromosomal mapping of the human macrophage scavenger receptor gene. J Biol Chem. 1993 Jan 25;268(3):2120-5.
88. Suzuki H, Kurihara Y, Takeya M, Kamada N, Kataoka M, Jishage K, Ueda O, Sakaguchi H, Higashi T, Suzuki T, Takashima Y, Kawabe Y, Cynshi O, Wada Y, Honda M, Kurihara H, Aburatani H, Doi T, Matsumoto A, Azuma S, Noda T, Toyoda Y, Itakura H, Yazaki Y, Kodama T. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature. 1997 Mar 20;386(6622):292-6.
89. Dunne DW, Resnick D, Greenberg J, Krieger M, Joiner KA. The type I macrophage scavenger receptor binds to gram-positive bacteria and recognizes lipoteichoic acid. Proc Natl Acad Sci U S A. 1994 Mar 1;91(5):1863-7.
90. Hampton RY, Golenbock DT, Penman M, Krieger M, Raetz CR. Recognition and plasma clearance of endotoxin by scavenger receptors. Nature. 1991 Jul 25;352(6333):342-4.
91. Peiser L, De Winther MP, Makepeace K, Hollinshead M, Coull P, Plested J, Kodama T, Moxon ER, Gordon S. The class A macrophage scavenger receptor is a major pattern recognition receptor for Neisseria meningitidis which is independent of lipopolysaccharide and not required for secretory responses. Infect Immun. 2002 Oct;70(10):5346-54.
92. Plüddemann A, Mukhopadhyay S, Sankala M, Savino S, Pizza M, Rappuoli R, Tryggvason K, Gordon S. SR-A, MARCO and TLRs differentially recognise selected surface proteins from Neisseria meningitidis: an example of fine specificity in microbial ligand recognition by innate immune receptors. J Innate Immun. 2009;1(2):153-63.
93. Limmon GV, Arredouani M, McCann KL, Corn Minor RA, Kobzik L, Imani F. Scavenger receptor class-A is a novel cell surface receptor for double-stranded RNA. FASEB J. 2008 Jan;22(1):159-67.
94. DeWitte-Orr SJ, Collins SE, Bauer CM, Bowdish DM, Mossman KL. An accessory to the 'Trinity': SR-As are essential pathogen sensors of extracellular dsRNA, mediating entry and leading to subsequent type I IFN responses. PLoS Pathog. 2010 Mar 26;6(3):e1000829.
95. Haisma HJ, Boesjes M, Beerens AM, van der Strate BW, Curiel DT, Plüddemann A, Gordon S, Bellu AR. Scavenger receptor A: a new route for adenovirus 5. Mol Pharm. 2009 Mar-Apr;6(2):366-74.
96. Thomas CA, Li Y, Kodama T, Suzuki H, Silverstein SC, El Khoury J. Protection from lethal gram-positive infection by macrophage scavenger receptor-dependent phagocytosis. J Exp Med. 2000 Jan 3;191(1):147-56.
97. Ozment TR, Ha T, Breuel KF, Ford TR, Ferguson DA, Kalbfleisch J, Schweitzer JB, Kelley JL, Li C, Williams DL. Scavenger receptor class a plays a central role in mediating mortality and the development of the pro-inflammatory pheno-type in polymicrobial sepsis. PLoS Pathog. 2012 Oct;8(10):e1002967.
98. Yu H, Ha T, Liu L, Wang X, Gao M, Kelley J, Kao R, Williams D, Li C. Scavenger receptor A (SR-A) is required for LPS-induced TLR4 mediated NF-kappaB activation in macrophages. Biochim Biophys Acta. 2012 Jul;1823(7):1192-8.
99. Yu X, Yi H, Guo C, Zuo D, Wang Y, Kim HL, Subjeck JR, Wang XY. Pattern recognition scavenger receptor CD204 attenuates Toll-like receptor 4-induced NF-kappaB activation by directly inhibiting ubiquitination of tumor necrosis factor (TNF) receptor-associated factor 6. J Biol Chem. 2011 May 27;286(21):18795-806.
100. Mukhopadhyay S, Varin A, Chen Y, Liu B, Tryggvason K, Gordon S. SR-A/MARCO-mediated ligand delivery enhances intracellular TLR and NLR function, but ligand scavenging from cell surface limits TLR4 response to pathogens. Blood. 2011 Jan 27;117(4):1319-28.
101. Chen Y, Wermeling F, Sundqvist J, Jonsson AB, Tryggvason K, Pikkarainen T, Karlsson MC. A regulatory role for macrophage class A scavenger receptors in TLR4-mediated LPS responses. Eur J Immunol. 2010 May;40(5):1451-60.
102. Levy-Barazany H, Frenkel D. Expression of scavenger receptor A on antigen presenting cells is important for CD4+ T-cells proliferation in EAE mouse model. J Neuroinflammation. 2012 Jun 7;9:120-8.
103. Nicoletti A, Caligiuri G, Tornberg I, Kodama T, Stemme S, Hansson GK. The macrophage scavenger receptor type A directs modified proteins to antigen presentation. Eur J Immunol. 1999 Feb;29(2):512-21.
104. Freigang S, Landais E, Zadorozhny V, Kain L, Yoshida K, Liu Y, Deng S, Palinski W, Savage PB, Bendelac A, Teyton L. Scavenger receptors target glycolipids for natural killer T cell activation. J Clin Invest. 2012;122(11):3943-54.
105. Adachi H, Tsujimoto M. Characterization of the human gene encoding the scavenger receptor expressed by endothelial cell and its regulation by a novel transcription factor, endothelial zinc finger protein-2. J Biol Chem. 2002 Jul 5;277(27):24014-21.
106. Adachi H, Tsujimoto M, Arai H, Inoue K. Expression cloning of a novel scavenger receptor from human endothelial cells. J Biol Chem. 1997 Dec 12;272(50):31217-20.
107. Tamura Y, Osuga J, Adachi H, Tozawa R, Takanezawa Y, Ohashi K, Yahagi N, Sekiya M, Okazaki H, Tomita S, Iizuka Y, Koizumi H, Inaba T, Yagyu H, Kamada N, Suzuki H, Shimano H, Kadowaki T, Tsujimoto M, Arai H, Yamada N, Ishibashi S. Scavenger receptor expressed by endothelial cells I (SREC-I) mediates the uptake of acetylated low density lipoproteins by macrophages stimulated with lipopolysaccharide. J Biol Chem. 2004 Jul 23;279(30):30938-44.
108. Berwin B, Delneste Y, Lovingood RV, Post SR, Pizzo SV. SREC-I, a type F scavenger receptor, is an endocytic receptor for calreticulin. J Biol Chem. 2004 Dec 3;279(49):51250-7.
109. Facciponte JG, Wang XY, Subjeck JR. Hsp110 and Grp170, members of the Hsp70 superfam-ily, bind to scavenger receptor-A and scavenger receptor expressed by endothelial cells-I. Eur J Immunol. 2007 Aug;37(8):2268-79.
110. Murshid A, Gong J, Calderwood SK. Heat shock protein 90 mediates efficient antigen cross presentation through the scavenger receptor expressed by endothelial cells-I. J Immunol. 2012 Sep 1;185(5):2903-17.
111. Pfistershammer K, Klauser C, Leitner J, Stöckl J, Majdic O, Weichhart T, Sobanov Y, Bochkov V, Säemann M, Zlabinger G, Steinberger P. Identification of the scavenger receptors SREC-I, Cla-1 (SR-BI), and SR-AI as cellular receptors for Tamm-Horsfall protein. J Leukoc Biol. 2008 Jan;83(1):131-8.
112. Hölzl MA, Hofer J, Kovarik JJ, Roggenbuck D, Reinhold D, Goihl A, Gärtner M, Steinberger P, Zlabinger GJ. The zymogen granule protein 2 (GP2) binds to scavenger receptor expressed on endothelial cells I (SREC-I). Cell Immunol. 2011;267(2):88-93.
113. Means TK, Mylonakis E, Tampakakis E, Colvin RA, Seung E, Puckett L, Tai MF, Stewart CR, Pukkila-Worley R, Hickman SE, Moore KJ, Calderwood SB, Hacohen N, Luster AD, El Khoury J. Evolutionarily conserved recognition and innate immunity to fungal pathogens by the scavenger receptors SCARF1 and CD36. J Exp Med. 2009 Mar 16;206(3):637-53.
114. Beauvillain C, Meloni F, Sirard JC, Blanchard S, Jarry U, Scotet M, Magistrelli G, Delneste Y, Barnaba V, Jeannin P. The scavenger receptors SRA-1 and SREC-I cooperate with TLR2 in the recognition of the hepatitis C virus non-structural protein 3 by dendritic cells. J Hepatol. 2010;52(5):644-51.
115. Dolganiuc A, Oak S, Kodys K, Golenbock DT, Finberg RW, Kurt-Jones E, Szabo G. Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation. Gastroenterology. 2004;127(5):1513-24.
116. Chang S, Dolganiuc A, Szabo G. Toll-like receptors 1 and 6 are involved in TLR2-mediated macrophage activation by hepatitis C virus core and NS3 proteins. J Leukocyte Biol. 2007;82(3):479-87.
117. Chung H, Watanabe T, Kudo M, Chiba T. Hepatitis C virus core protein induces homotol-erance and cross-tolerance to toll-like receptor ligands by activation of toll-like receptor 2. J Infect Diseases. 2010; 202(6):853-61.
118. Accapezzato D, Visco V, Francavilla V, Molette C, Donato T, Paroli M, Mondelli MU, Doria M, Torrisi MR, Barnaba V. Chloroquine enhances human CD8+ T cell responses against soluble antigens in vivo. J Exp Med. 2005 202(6):817-28.
119. Spadaro F, Lapenta C, Donati S, Abalsamo L, Barnaba V, Belardelli F, Santini SM, Ferrantini M. IFN-α enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing. Blood. 2012 119(6):1407-17.
120. Gressner AM, Weiskirchen R. Modern patho-genetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med. 2006 Jan-Mar;10(1):76-99.
121. Gieseler RK, Marquitan G, Schlattjan M, Sowa J P, Bechmann LP, Timm J, Roggendorf M, Gerken G, Friedman SL, Canbay A. Hepatocyte apoptotic bodies encasing nonstructural HCV proteins amplify hepatic stellate cell activation: implications for chronic hepatitis C. J Viral Hepatitis. 2011 18(11):760-7.
122. Miquilena-Colina ME, Lima-Cabello E, Sánchez-Campos S, García-Mediavilla MV, Fernández-Bermejo M, Lozano-Rodríguez T, Vargas-Castrillón J, Buqué X, Ochoa B, Aspichueta P, González-Gallego J, García-Monzón C. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in nonalcoholic steatohepatitis and chronic hepatitis C. Gut. 2011 60(10):1394-402.
123. Silverstein RL, Febbraio M. CD36, a scavenger receptor involved in immunity, metabolism, angio-genesis, and behavior. Sci Signal. 2009 2(72).
124. Tsuji T, Osawa T. Purification and chemical char-acterization of human platelet membrane glyco-protein IV. J Biochem. 1986 Oct;100(4):1077-85.
125. Tandon NN, Lipsky RH, Burgess WH, Jamieson GA. Isolation and characterization of platelet glycoprotein IV (CD36). J Biol Chem. 1989 May 5;264(13):7570-5.
126. Asch AS, Barnwell J, Silverstein RL, Nachman RL. Isolation of the thrombospondin membrane receptor. J Clin Invest. 1987 Apr;79(4):1054-61.
127. Barnwell JW, Asch AS, Nachman RL, Yamaya M, Aikawa M, Ingravallo P. A human 88-kD membrane glycoprotein (CD36) functions in vitro as a receptor for a cytoadherence ligand on Plasmodium falciparum-infected erythrocytes. J Clin Invest. 1989 Sep;84(3):765-72.
128. Ockenhouse CF, Tandon NN, Magowan C, Jamieson GA, Chulay JD. Identification of a platelet membrane glycoprotein as a falciparum malaria sequestration receptor. Science. 1989 Mar 17;243(4897):1469-71.
129. Oquendo P, Hundt E, Lawler J, Seed B. CD36 directly mediates cytoadherence of Plasmodium falciparum parasitized erythrocytes. Cell. 1989 Jul 14;58(1):95-101.
130. Handunnetti SM, van Schravendijk MR, Hasler T, Barnwell JW, Greenwalt DE, Howard RJ. Involvement of CD36 on erythrocytes as a roset-ting receptor for Plasmodium falciparum-infected erythrocytes. Blood. 1992 Oct 15;80(8):2097-104.
131. Hoebe K, Georgel P, Rutschmann S, Du X, Mudd S, Crozat K, Sovath S, Shamel L, Hartung T, Zähringer U, Beutler B. CD36 is a sensor of diac-ylglycerides. Nature. 2005 Feb 3;433(7025):523-7.
132. Mikoajczyk TP, Skrzeczyńska-Moncznik JE, Zarebski MA, Marewicz EA, Wiśniewska AM, Dzieba M, Dobrucki JW, Pryjma JR. Interaction of human peripheral blood monocytes with apoptotic polymorphonuclear cells. Immunology. 2009;128(1):103-13.
133. Savill J, Hogg N, Ren Y, Haslett C. Thrombospondin cooperates with CD36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis. J Clin Invest. 1992 Oct;90(4):1513-22.
134. Tandon NN, Kralisz U, Jamieson GA. Identification of glycoprotein IV (CD36) as a primary receptor for platelet-collagen adhesion. J Biol Chem. 1989 May 5;264(13):7576-83.
135. Endemann G, Stanton LW, Madden KS, Bryant CM, White RT, Protter AA. CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem. 1993 Jun 5;268(16):11811-6.
136. Silverstein RL. Inflammation, atherosclerosis, and arterial thrombosis: Role of the scavenger receptor CD36. Cleveland Clin J Med. 2009 76(Suppl 2):S27-30.
137. Silverstein RL, Li W, Park YM, Rahaman SO. Mechanisms of cell signaling by the scavenger receptor CD36: implications in atherosclerosis and thrombosis. Trans Am Clin Climatol Assoc. 2010;121:206-20.
138. Stuart LM, Deng J, Silver JM, Takahashi K, Tseng AA, Hennessy EJ, Ezekowitz RA, Moore KJ. Response to Staphylococcus aureus requires CD36-mediated phagocytosis triggered by the COOH-terminal cytoplasmic domain. J Cell Biol. 2005 Aug 1;170(3):477-85.
139. Jimenez-Dalmaroni MJ, Xiao N, Corper AL, Verdino P, Ainge GD, Larsen DS, Painter GF, Rudd PM, Dwek RA, Hoebe K, Beutler B, Wilson IA. Soluble CD36 ectodomain binds negatively charged diacylglycerol ligands and acts as a co-receptor for TLR2. PLoS One. 2009 Oct 22;4(10):e7411.
140. Triantafilou M, Gamper FG, Haston RM, Mouratis MA, Morath S, Hartung T, Triantafilou K. Membrane sorting of toll-like receptor (TLR)-2/6 and TLR2/1 heterodimers at the cell surface determines heterotypic associations with CD36 and intracellular targeting. J Biol Chem. 2006 Oct 13;281(41):31002-11.
141. Abe T, Shimamura M, Jackman K, Kurinami H, Anrather J, Zhou P, Iadecola C. Key role of CD36 in Toll-like receptor 2 signaling in cerebral ischemia. Stroke. 2010 May;41(5):898-904.
142. Seimon TA, Nadolski MJ, Liao X, Magallon J, Nguyen M, Feric NT, Koschinsky ML, Harkewicz R, Witztum JL, Tsimikas S, Golenbock D, Moore KJ, Tabas I. Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab. 2010 Nov 3;12(5):467-82.
143. Shamsul HM, Hasebe A, Iyori M, Ohtani M, Kiura K, Zhang D, Totsuka Y, Shibata K. The Toll-like receptor 2 (TLR2) ligand FSL-1 is internalized via the clathrin-dependent endocytic pathway triggered by CD14 and CD36 but not by TLR2. Immunology. 2010 Jun;130(2):262-72.
144. Abumrad NA, el-Maghrabi MR, Amri EZ, Lopez E, Grimaldi PA. Cloning of a rat adipo-cyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation. Homology with human CD36. J Biol Chem. 1993 Aug 25;268(24):17665-8.
145. Harmon CM, Abumrad NA. Binding of sulfo-succinimidyl fatty acids to adipocyte membrane proteins: isolation and amino-terminal sequence of an 88-kD protein implicated in transport of long-chain fatty acids. J Membr Biol. 1993 Apr;133(1):43-9.
146. Ibrahimi A, Bonen A, Blinn WD, Hajri T, Li X, Zhong K, Cameron R, Abumrad NA. Muscle-specific overexpression of FAT/CD36 enhances fatty acid oxidation by contracting muscle, reduces plasma triglycerides and fatty acids, and increases plasma glucose and insulin. J Biol Chem. 1999 274(38):26761-6.
147. Febbraio M, Abumrad NA, Hajjar DP, Sharma K, Cheng W, Pearce SF, Silverstein RL. A Null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J Biol Chem. 1999 274(27):19055-62.
148. Koonen DP, Jacobs RL, Febbraio M, Young ME, Soltys CL, Ong H, Vance DE, Dyck JR. Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity. Diabetes. 2007 56(12):2863-71.
149. Memon RA, Fuller J, Moser AH, Smith PJ, Grunfeld C, Feingold KR. Regulation of putative fatty acid transporters and Acyl-CoA synthetase in liver and adipose tissue in ob/ob mice. Diabetes. 1999 Jan;48(1):121-7.
150. Yu S, Matsusue K, Kashireddy P, Cao WQ, Yeldandi V, Yeldandi AV, Rao MS, Gonzalez FJ, Reddy JK. Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor Î31 (PPARÎ31) overexpression. J Biol Chem. 2003 278(1):498-505.
151. Zhang YL, Hernandez-Ono A, Siri P, Weisberg S, Conlon D, Graham MJ, Crooke RM, Huang LS, Ginsberg HN. Aberrant hepatic expression of PPARÎ32 stimulates hepatic lipogenesis in a mouse model of obesity, insulin resistance, dyslip-idemia, and hepatic steatosis. J Biol Chem. 2006 281(49):37603-15.
152. Zhou J, Febbraio M, Wada T, Zhai Y, Kuruba R, He J, Lee JH, Khadem S, Ren S, Li S, Silverstein RL, Xie W. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARÎ3 in promoting steatosis. Gastroenterology. 2008 134(2):556-67.
153. He J, Lee JH, Febbraio M, Xie W. The emerging roles of fatty acid translocase/CD36 and the aryl hydrocarbon receptor in fatty liver disease. Exp Biol Med (Maywood). 2011 236(10):1116-21.
154. Wouters K, van Gorp PJ, Bieghs V, Gijbels MJ, Duimel H, Lütjohann D, Kerksiek A, van Kruchten R, Maeda N, Staels B, van Bilsen M, Shiri-Sverdlov R, Hofker MH. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology. 2008 Aug;48(2):474-86.
155. Bieghs V, Wouters K, van Gorp PJ, Gijbels MJ, de Winther MP, Binder CJ, Lütjohann D, Febbraio M, Moore KJ, van Bilsen M, Hofker MH, Shiri-Sverdlov R. Role of scavenger receptor A and CD36 in diet-induced nonalcoholic steatohepa-titis in hyperlipidemic mice. Gastroenterology. 2010 Jun;138(7):2477-86.
156. Bieghs V, Verheyen F, van Gorp PJ, Hendrikx T, Wouters K, Lütjohann D, Gijbels MJ, Febbraio M, Binder CJ, Hofker MH, Shiri-Sverdlov R. Internalization of modified lipids by CD36 and SR-A leads to hepatic inflammation and lyso-somal cholesterol storage in Kupffer cells. PLoS One. 2012;7(3):e34378.
157. Chen GY, Nunez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol. 2010 Dec;10(12):826-37.
158. Stewart CR, Stuart LM, Wilkinson K, van Gils JM, Deng J, Halle A, Rayner KJ, Boyer L, Zhong R, Frazier WA, Lacy-Hulbert A, El Khoury J, Golenbock DT, Moore KJ. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol. 2009 Feb;11(2):155-61.
159. Fromenty B, Robin MA, Igoudjil A, Mansouri A, Pessayre D. The ins and outs of mitochondrial dysfunction in NASH. Diabetes Metab. 2004 Apr;30(2):121-38.
160. Schneiderhan W, Schmid-Kotsas A, Zhao J, Grünert A, Nüssler A, Weidenbach H, Menke A, Schmid RM, Adler G, Bachem MG. Oxidized low-density lipoproteins bind to the scavenger receptor, CD36, of hepatic stellate cells and stimulate extracellular matrix synthesis. Hepatology. 2001;34(4):729-37.
161. Kang Q, Chen A. Curcumin eliminates oxidized LDL roles in activating hepatic stellate cells by suppressing gene expression of lectin-like oxidized LDL receptor-1. Lab Invest. 2009;89(11):1275-90.
162. Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Aiba Y, Tanaka T, Miwa S, Katsura Y, Kita T, Masaki T. An endothelial receptor for oxidized low-density lipoprotein. Nature. 1997 Mar 6;386(6620):73-7.
163. Mehta JL, Chen J, Hermonat PL, Romeo F, Novelli G. Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): a critical player in the development of atherosclerosis and related disorders. Cardiovasc Res. 2006 69(1):36-45.
164. Wu Z, Sawamura T, Kurdowska AK, Ji HL, Idell S, Fu J. LOX-1 deletion improves neutro-phil responses, enhances bacterial clearance, and reduces lung injury in a murine polymicrobial sepsis model. Infect Immun. 2011 Jul;79(7):2865-70
165. Goyal T, Mitra S, Khaidakov M, Wang X, Singla S, Ding Z, Liu S, Mehta JL. Current concepts of the role of oxidized LDL Receptors in atherosclerosis. Curr Atheroscler Rep. 2012 April;14(2):150-159.
166. Campbell LA, Puolakkainen M, Lee A, Rosenfeld ME, Garrigues HJ, Kuo CC. Chlamydia pneumoniae binds to the lectin-like oxidized LDL receptor for infection of endothelial cells. Microbes Infect. 2012 Jan;14(1):43-9.
167. Zhu H, Lee C, Zhang D, Wu W, Wang L, Fang X, Xu X, Song D, Xie J, Ren S, Gu J. Surface-associated GroEL facilitates the adhesion of Escherichia coli to macrophages through lectin-like oxidized low-density lipoprotein receptor-1. Microbes Infect. 2013 March;15(3):172-80.
168. Murphy JE, Tacon D, Tedbury PR, Hadden JM, Knowling S, Sawamura T, Peckham M, Phillips SE, Walker JH, Ponnambalam S. LOX-1 scavenger receptor mediates calcium-dependent recognition of phosphatidylserine and apoptotic cells. Biochem J. 2006 Jan 1;393(Pt 1):107-15.
169. Takanabe-Mori R, Ono K, Sowa N, Wada H, Takaya T, Horie T, Satoh-Asahara N, Shimatsu A, Fujita M, Sawamura T, Hasegawa K. Lectin-like oxidized low-density lipoprotein receptor-1 is required for the adipose tissue expression of pro-inflammatory cytokines in high-fat diet-induced obese mice. Biochem Biophys Res Commun. 2010 Jul 30;398(3):576-80.
170. Rasouli N, Yao-Borengasser A, Varma V, Spencer HJ, McGehee RE Jr, Peterson CA, Mehta JL, Kern PA. Association of scavenger receptors in adipose tissue with insulin resistance in nondia-betic humans. Arterioscler Thromb Vasc Biol. 2009 Sep;29(9):1328-35.
171. Khaidakov M, Mitra S, Kang BY, Wang X, Kadlubar S, Novelli G, Raj V, Winters M, Carter WC, Mehta JL. Oxidized LDL receptor 1 (OLR1) as a possible link between obesity, dyslip-idemia and cancer. PLoS One. 2011;6(5):e20277.
172. Lu J, Mehta JL. LOX-1: a critical player in the genesis and progression of myocardial ischemia. Cardiovasc Drugs Ther. 2011 Oct;25(5):431-40.
173. Lu J, Wang X, Wang W, Muniyappa H, Deshmukh A, Hu C, Das K, Mehta JL. Abrogation of lectin-like oxidized LDL receptor-1 attenuates acute myocardial ischemia-induced renal dysfunction by modulating systemic and local inflammation. Kidney Int. 2012 Aug;82(4):436-44.
174. Wang X, Khaidakov M, Ding Z, Mitra S, Lu J, Dai Y, Mehta JL. Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) and cardiac fibroblast growth/novelty and significance. Hypertension. 2012 60(6):1437-42.
175. Duryee MJ, Klassen LW, Thiele GM. Immunological response in alcoholic liver disease. World J Gastroenterol. 2007 Oct 7;13(37):4938-46.
176. Duryee MJ, Freeman TL, Willis MS, Hunter CD, Hamilton BC 3rd, Suzuki H, Tuma DJ, Klassen LW, Thiele GM. Scavenger receptors on sinusoidal liver endothelial cells are involved in the uptake of aldehyde-modified proteins. Mol Pharmacol. 2005 68(5):1423-30.
177. Duryee MJ, Klassen LW, Freeman TL, Willis MS, Tuma DJ, Thiele GM. Chronic ethanol consumption impairs receptor-mediated endocytosis of MAA-modified albumin by liver endothelial cells. Biochem Pharmacol. 2003 Sep 15;66(6):1045-54.
178. Duryee MJ, Willis MS, Freeman TL, Kuszynski CA, Tuma DJ, Klassen LW, Thiele GM. Mechanisms of alcohol liver damage: aldehydes, scavenger receptors, and autoimmunity. Front Biosci. 2004 Sep 1;9:3145-55.
179. Akila P, Prashant V, Suma MN, Prashant SN, Chaitra TR. CD163 and its expanding functional repertoire. Clin Chim Acta. 2012 Apr 11;413(7-8):669-74.
180. Van Gorp H, Delputte PL, Nauwynck HJ. Scavenger receptor CD163, a Jack-of-all-trades and potential target for cell-directed therapy. Mol Immunol. 2010 Apr;47(7-8):1650-60.
181. Law SK, Micklem KJ, Shaw JM, Zhang XP, Dong Y, Willis AC, Mason DY. A new macrophage differentiation antigen which is a member of the scavenger receptor superfamily. Eur J Immunol. 1993 Sep;23(9):2320-5.
182. Handberg A, Levin K, Hojlund K, Beck-Nielsen H. Identification of the oxidized low-density lipoprotein scavenger receptor CD36 in plasma: a novel marker of insulin resistance. Circulation. 2006 Sep 12;114(11):1169-76.
183. Backe E, Schwarting R, Gerdes J, Ernst M, Stein H. Ber-MAC3: new monoclonal antibody that defines human monocyte/macrophage differentiation antigen. J Clin Pathol. 1991 Nov;44(11):936-45.
184. Hogger P, Dreier J, Droste A, Buck F, Sorg C. Identification of the integral membrane protein RM3/1 on human monocytes as a glucocorticoid-inducible member of the scavenger receptor cysteine-rich family (CD163). J Immunol. 1998 Aug 15;161(4):1883-90.
185. Moniuszko M, Kowal K, Rusak M, Pietruczuk M, Dabrowska M, Bodzenta-Lukaszyk A. Monocyte CD163 and CD36 expression in human whole blood and isolated mononuclear cell samples: influence of different anticoagulants. Clin Vaccine Immunol. 2006 Jun;13(6):704-7.
186. Sulahian TH, Högger P, Wahner AE, Wardwell K, Goulding NJ, Sorg C, Droste A, Stehling M, Wallace PK, Morganelli PM, Guyre PM. Human monocytes express CD163, which is upregulated by IL-10 and identical to p155. Cytokine. 2000 Sep;12(9):1312-21.
187. Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK, Moestrup SK. Identification of the haemoglobin scavenger receptor. Nature. 2001 Jan 11;409(6817):198-201.
188. Madsen M, Møller HJ, Nielsen MJ, Jacobsen C, Graversen JH, van den Berg T, Moestrup SK. Molecular characterization of the haptoglobin. hemoglobin receptor CD163. Ligand binding properties of the scavenger receptor cysteine-rich domain region. J Biol Chem. 2004 Dec 3;279(49):51561-7.
189. Wagener FA, Volk HD, Willis D, Abraham NG, Soares MP, Adema GJ, Figdor CG. Different faces of the heme-heme oxygenase system in inflammation. Pharmacol Rev. 2003 Sep;55(3):551-71.
190. Chasis JA. Erythroblastic islands: specialized microenvironmental niches for erythropoiesis. Curr Opin Hematol. 2006 May;13(3):137-41.
191. Fabriek BO, Polfliet MM, Vloet RP, van der Schors RC, Ligtenberg AJ, Weaver LK, Geest C, Matsuno K, Moestrup SK, Dijkstra CD, van den Berg TK. The macrophage CD163 surface glycoprotein is an erythroblast adhesion receptor. Blood. 2007 Jun 15;109(12):5223-9.
192. Buechler C, Ritter M, Orso E, Langmann T, Klucken J, Schmitz G. Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and antiinflammatory stimuli. J Leukoc Biol. 2000 Jan;67(1):97-103.
193. Williams L, Jarai G, Smith A, Finan P. IL-10 expression profiling in human monocytes. J Leukoc Biol. 2002 Oct;72(4):800-9.
194. Gleissner CA, Shaked I, Erbel C, Bockler D, Katus HA, Ley K. CXCL4 downregulates the atheroprotective hemoglobin receptor CD163 in human macrophages. Circ Res. 2010 Jan 8;106(1):203-11.
195. Bover LC, Cardó-Vila M, Kuniyasu A, Sun J, Rangel R, Takeya M, Aggarwal BB, Arap W, Pasqualini R. A previously unrecognized proteinprotein interaction between TWEAK and CD163: potential biological implications. J Immunol. 2007 Jun 15;178(12):8183-94.
196. Fabriek BO, van Bruggen R, Deng DM, Ligtenberg AJ, Nazmi K, Schornagel K, Vloet RP, Dijkstra CD, van den Berg TK. The macro-phage scavenger receptor CD163 functions as an innate immune sensor for bacteria. Blood. 2009 Jan 22;113(4):887-92.
197. Moller HJ. Soluble CD163. Scand J Clin Lab Invest. 2012 Feb;72(1):1-13.
198. Moller HJ, Peterslund NA, Graversen JH, Moestrup SK. Identification of the hemoglobin scavenger receptor/CD163 as a natural soluble protein in plasma. Blood. 2002 Jan 1;99(1):378-80.
199. Daly A, Walsh C, Feighery C, O'Shea U, Jackson J, Whelan A. Serum levels of soluble CD163 correlate with the inflammatory process in coeliac disease. Aliment Pharmacol Ther. 2006 Aug1;24(3):553-9.
200. Fabriek BO, Møller HJ, Vloet RP, van Winsen LM, Hanemaaijer R, Teunissen CE, Uitdehaag BM, van den Berg TK, Dijkstra CD. Proteolytic shedding of the macrophage scavenger receptor CD163 in multiple sclerosis. J Neuroimmunol. 2007 Jul;187(1-2):179-86.
201. Matsushita N, Kashiwagi M, Wait R, Nagayoshi R, Nakamura M, Matsuda T, Hogger P, Guyre PM, Nagase H, Matsuyama T. Elevated levels of soluble CD163 in sera and fluids from rheumatoid arthritis patients and inhibition of the shedding of CD163 by TIMP-3. Clin Exp Immunol. 2002 Oct;130(1):156-61.
202. Hiraoka A, Horiike N, Akbar SM, Michitaka K, Matsuyama T, Onji M. Soluble CD163 in patients with liver diseases: very high levels of soluble CD163 in patients with fulminant hepatic failure. J Gastroenterol. 2005 Jan;40(1):52-6.
203. Møller HJ, Grønbaek H, Schiødt FV, HollandFischer P, Schilsky M, Munoz S, Hassanein T, Lee WM; U.S. Acute Liver Failure Study Group. Soluble CD163 from activated macrophages predicts mortality in acute liver failure. J Hepatol. 2007 Nov;47(5):671-6.
204. Gronbaek H, Sandahl TD, Mortensen C, Vilstrup H, Moller HJ, Moller S. Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis. Aliment Pharmacol Ther. 2012 Jul;36(2):173-80.
205. Holland-Fischer P, Grønbæk H, Sandahl TD, Moestrup SK, Riggio O, Ridola L, Aagaard NK, Møller HJ, Vilstrup H. Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS. Gut. 2011 Oct;60(10):1389-93.
206. Hiraoka A, Horiike N, Akbar SM, Michitaka K, Matsuyama T, Onji M. Expression of CD163 in the liver of patients with viral hepatitis. Pathol Res Pract. 2005;201(5):379-84.
207. Melino M, Gadd VL, Walker GV, Skoien R, Barrie HD, Jothimani D, Horsfall L, Jones A, Sweet MJ, Thomas GP, Clouston AD, Jonsson JR, Powell EE. Macrophage secretory products induce an inflammatory phenotype in hepatocytes. World J Gastroenterol. 2012 Apr 21;18(15):1732-44.
208. De Vito R, Alisi A, Masotti A, Ceccarelli S, Panera N, Citti A, Salata M, Valenti L, Feldstein AE, Nobili V. Markers of activated inflammatory cells correlate with severity of liver damage in children with nonalcoholic fatty liver disease. Int J Mol Med. 2012 Jul;30(1):49-56.
209. Motomura T, Shirabe K, Mano Y, Muto J, Toshima T, Umemoto Y, Fukuhara T, Uchiyama H, Ikegami T, Yoshizumi T, Soejima Y, Maehara Y. Neutrophil-lymphocyte ratio reflects hepatocellu-lar carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol. 2013 Jan;58(1):58-64.
210. Bertuzzo VR, Cescon M, Ravaioli M, Grazi GL, Ercolani G, Del Gaudio M, Cucchetti A, D'Errico-Grigioni A, Golfieri R, Pinna AD. Analysis of factors affecting recurrence of hepa-tocellular carcinoma after liver transplantation with a special focus on inflammation markers. Transplantation. 2011 Jun 15;91(11):1279-85.
211. Gomez D, Farid S, Malik HZ, Young AL, Toogood GJ, Lodge JP, Prasad KR. Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg. 2008 Aug;32(8):1757-62.
212. Wang GY, Yang Y, Li H, Zhang J, Jiang N, Li MR, Zhu HB, Zhang Q, Chen GH. A scoring model based on neutrophil to lymphocyte ratio predicts recurrence of HBV-associated hepatocel-lular carcinoma after liver transplantation. PLoS One. 2011;6(9):e25295.
213. Muller SA, Sasaki T, Bork P, Wolpensinger B, Schulthess T, Timpl R, Engel A, Engel J. Domain organization of Mac-2 binding protein and its oligomerization to linear and ring-like structures. J Mol Biol. 1999 Aug 27;291(4):801-13.
214. Koths K, Taylor E, Halenbeck R, Casipit C, Wang A. Cloning and characterization of a human Mac-2-binding protein, a new member of the superfamily defined by the macrophage scavenger receptor cysteine-rich domain. J Biol Chem. 1993 Jul 5;268(19):14245-9.
215. Friedman J, Trahey M, Weissman I. Cloning and characterization of cyclophilin C-associated protein: a candidate natural cellular ligand for cyclophilin C. Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6815-9.
216. Ullrich A, Sures I, D'Egidio M, Jallal B, Powell TJ, Herbst R, Dreps A, Azam M, Rubinstein M, Natoli C, Shawver L, Schlessinger J, Iacobelli S. The secreted tumor-associated antigen 90K is a potent immune stimulator. J Biol Chem. 1994 Jul 15;269(28):18401-7.
217. Iacobelli S, Arno E, D'Orazio A, Coletti G. Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer. Cancer Res. 1986 Jun;46(6):3005-10.
218. Linsley PS, Horn D, Marquardt H, Brown JP, Hellstrom I, Hellstrom KE, Ochs V, Tolentino E. Identification of a novel serum protein secreted by lung carcinoma cells. Biochemistry. 1986 May 20;25(10):2978-86.
219. Natali PG, Wilson BS, Imai K, Bigotti A, Ferrone S. Tissue distribution, molecular profile, and shed-ding of a cytoplasmic antigen identified by the monoclonal antibody 465.12S to human melanoma cells. Cancer Res. 1982 Feb;42(2):583-9.
220. Iacobelli S, Sismondi P, Giai M, D'Egidio M, Tinari N, Amatetti C, Di Stefano P, Natoli C. Prognostic value of a novel circulating serum 90K antigen in breast cancer. Br J Cancer 1994 Jan;69(1):172-6.
221. Park YP, Choi SC, Kim JH, Song EY, Kim JW, Yoon DY, Yeom YI, Lim JS, Kim JW, Paik SG, Lee HG. Up-regulation of Mac-2 binding protein by hTERT in gastric cancer. Int J Cancer. 2007 Feb 15;120(4):813-20.
222. Gentiloni N, Caradonna P, Costamagna G, D'Ostilio N, Perri V, Mutignani M, Febbraro S, Tinari N, Iacobelli S, Natoli C. Pancreatic juice 90K and serum CA 19-9 combined determination can discriminate between pancreatic cancer and chronic pancreatitis. Am J Gastroenterol. 1995 Jul;90(7):1069-72.
223. Sardana G, Marshall J, Diamandis EP. Discovery of candidate tumor markers for prostate cancer via proteomic analysis of cell culture-conditioned medium. Clin Chem. 2007 Mar;53(3):429-37.
224. Ozaki Y, Kontani K, Teramoto K, Fujita T, Tezuka N, Sawai S, Maeda T, Watanabe H, Fujino S, Asai T, Ohkubo I. Involvement of 90K/Mac-2 binding protein in cancer metastases by increased cellular adhesiveness in lung cancer. Oncol Rep. 2004 Nov;12(5):1071-7.
225. Srirajaskanthan R, Caplin ME, Waugh MG, Watkins J, Meyer T, Hsuan JJ, Beaumont NJ. Identification of Mac-2-binding protein as a putative marker of neuroendocrine tumors from the analysis of cell line secretomes. Mol Cell Proteomics. 2010 Apr;9(4):656-66.
226. Scambia G, Panici PB, Baiocchi G, Perrone L, Iacobelli S, Mancuso S. Measurement of a monoclonal-antibody-defined antigen (90K) in the sera of patients with ovarian cancer. Anticancer Res. 1988 Jul-Aug;8(4):761-4.
227. Sasaki T, Brakebusch C, Engel J, Timpl R. Mac-2 binding protein is a cell-adhesive protein of the extracellular matrix which self-assembles into ring-like structures and binds beta1 integrins, collagens and fibronectin. EMBO J. 1998 Mar 16;17(6):1606-13.
228. Fornarini B, D'Ambrosio C, Natoli C, Tinari N, Silingardi V, Iacobelli S. Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. Blood 2000 Nov 1;96(9):3282-5.
229. Inohara H, Akahani S, Koths K, Raz A. Interactions between galectin-3 and Mac-2-binding protein mediate cell-cell adhesion. Cancer Res. 1996 Oct 1;56(19):4530-4.
230. Rosenberg I, Cherayil BJ, Isselbacher KJ, Pillai S. Mac-2-binding glycoproteins. Putative ligands for a cytosolic beta-galactoside lectin. J Biol Chem. 1991 Oct 5;266(28):18731-6.
231. Tinari N, Kuwabara I, Huflejt ME, Shen PF, Iacobelli S, Liu F T. Glycoprotein 90K/MAC-2BP interacts with galectin-1 and mediates galectin-1-induced cell aggregation. Int J Cancer. 2001 Jan 15;91(2):167-72.
232. Jallal B, Powell J, Zachwieja J, Brakebusch C, Germain L, Jacobs J, Iacobelli S, Ullrich A. Suppression of tumor growth in vivo by local and systemic 90K level increase. Cancer Res. 1995 Aug 1;55(15):3223-7.
233. Yu B, Wright SD. LPS-dependent interaction of Mac-2-binding protein with immobilized CD14. J Inflamm. 1995;45(2):115-25.
234. Trahey M, Weissman IL. Cyclophilin C-associated protein: a normal secreted glycoprotein that down-modulates endotoxin and proinflamma-tory responses in vivo. Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):3006-11.
235. Darcissac EC, Vidal V, De La Tribonniere X, Mouton Y, Bahr GM. Variations in serum IL-7 and 90K/Mac-2 binding protein (Mac-2 BP) levels analysed in cohorts of HIV-1 patients and correlated with clinical changes following antiretroviral therapy. Clin Exp Immunol. 2001 Nov;126(2):287-94.
236. Dorrucci M, Ciccozzi M, Iacobelli S, Rezza G. Temporal trend in the level of 90K glycoprotein after HIV seroconversion among persons coin-fected with hepatitis C virus. Infection. 2005 Apr;33(2):101-2.
237. Dorrucci M, Iacobelli S, Suligoi B, Pezzotti P, Sinicco A, Angarano G, Tinari N, Rezza G. Longitudinal analysis of the 90K glycoprotein in the Italian HIV-seroconversion study: temporal trend and predictability of the maturity of HIV infection. J Biol Regul Homeost Agents. 2004 Jan-Mar;18(1):18-25.
238. Gröschel B, Braner JJ, Funk M, Linde R, Doerr HW, Cinatl J Jr, Iacobelli S. Elevated plasma levels of 90K (Mac-2 BP) immunostimulatory glycoprotein in HIV-1-infected children. J Clin Immunol. 2000 Mar;20(2):117-22.
239. Longo G, Natoli C, Rafanelli D, Tinari N, Morfini M, Rossi-Ferrini P, D'Ostilio N, Iacobelli S. Prognostic value of a novel circulating serum 90K antigen in HIV-infected haemophilia patients. Br J Haematol. 1993 Sep;85(1):207-9.
240. Iacobelli S, Natoli C, D'Egidio M, Tamburrini E, Antinori A, Ortona L. Lipoprotein 90K in human immunodeficiency virus-infected patients: a further serologic marker of progression. J Infect Dis. 1991 Oct;164(4):819.
241. Altindag ZZ, Marth C, Werner-Felmayer G, Natoli C, Zeimet AG, Wachter H, Iacobelli S, Fuchs D. Tumor-associated antigen 90K activates myelomonocytic cell line THP-1. Cancer Lett. 1996 Oct 1;107(1):143-8.
242. Powell TJ, Schreck R, McCall M, Hui T, Rice A, App H, Azam M, Ullrich A, Shawver LK. A tumor-derived protein which provides T-cell costimulation through accessory cell activation. J Immunother Emphasis Tumor Immunol. 1995 May;17(4):209-21.
243. Silvestri B, Calderazzo F, Coppola V, Rosato A, Iacobelli S, Natoli C, Ullrich A, Sures I, Azam M, Brakebush C, Chieco-Bianchi L, Amadori A. Differential effect on TCR:CD3 stimulation of a 90-kD glycoprotein (gp90/Mac-2BP), a member of the scavenger receptor cysteine-rich domain protein family. Clin Exp Immunol. 1998 Sep;113(3):394-400.
244. Natoli C, Iacobelli S, Kohn L. The immune stimulatory protein 90K increases major histo-compatibility complex class I expression in a human breast cancer cell line. Biochem Biophys Res Commun. 1996 Aug 14;225(2):617-20.
245. Grassadonia A, Tinari N, Fiorentino B, Suzuki K, Nakazato M, De Tursi M, Giuliani C, Napolitano G, Singer DS, Iacobelli S, Kohn LD. The 90K protein increases major histocompatibility complex class I expression and is regulated by hormones, gamma-interferon, and double-strand polynucleo-tides. Endocrinology. 2004 Oct;145(10):4728-36.
246. Kittl EM, Hofmann J, Hartmann G, Sebesta C, Beer F, Bauer K, Huber KR. Serum protein 90K/ Mac-2BP is an independent predictor of disease severity during hepatitis C virus infection. Clin Chem Lab Med. 2000 Mar;38(3):205-8.
247. Artini M, Natoli C, Tinari N, Costanzo A, Marinelli R, Balsano C, Porcari P, Angelucci D, D'Egidio M, Levrero M, Iacobelli S. Elevated serum levels of 90K/MAC-2 BP predict unre-sponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients. J Hepatol. 1996 Aug;25(2):212-7.
248. Correale M, Giannuzzi V, Iacovazzi PA, Valenza MA, Lanzillotta S, Abbate I, Quaranta M, Caruso ML, Elba S, Manghisi OG. I. Serum 90K/ MAC-2BP glycoprotein levels in hepatocellular carcinoma and cirrhosis. Anticancer Res. 1999 Jul-Aug;19(4C):3469-72.
249. Valentini AM, Iacovazzi PA, Correale M, Pirrelli M, Armentano R, Iacobelli S, Tinari N, Iurisci I, Caruso ML. Immunohistochemical and sero-logical 90K/Mac-2BP detection in hepatocel-lular carcinoma patients: different behaviour of two monoclonal antibodies. Med Chem. 2005 Mar;1(2):185-9.
250. Koopmann J, Thuluvath PJ, Zahurak ML, Kristiansen TZ, Pandey A, Schulick R, Argani P, Hidalgo M, Iacobelli S, Goggins M, Maitra A. Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma. Cancer. 2004;101(7):1609-15.
251. Alkhatatbeh MJ, Mhaidat NM, Enjeti AK, Lincz LF, Thorne RF. The putative diabetic plasma marker, soluble CD36, is non-cleaved, non-soluble and entirely associated with microparticles. J Thromb Haemost. 2011 Apr;9(4):844-51.
252. Fernandez-Real JM, Handberg A, Ortega F, Hojlund K, Vendrell J, Ricart W. Circulating soluble CD36 is a novel marker of liver injury in subjects with altered glucose tolerance. J Nutr Biochem. 2009 Jun;20(6):477-84.
253. Handberg A, Højlund K, Gastaldelli A, Flyvbjerg A, Dekker JM, Petrie J, Piatti P, Beck-Nielsen H; RISC Investigators. Plasma sCD36 is associated with markers of atherosclerosis, insulin resis-tance and fatty liver in a nondiabetic healthy population. J Intern Med. 2012 Mar;271(3):294-304.
254. Bassyouni IH, Gheita TA, Talaat RM. Clinical significance of serum levels of sCD36 in patients with systemic sclerosis: preliminary data. Rheumatology (Oxford). 2011 Nov;50(11):2108-12.
255. Liani R, Halvorsen B, Sestili S, Handberg A, Santilli F, Vazzana N, Formoso G, Aukrust P, Davì G. Plasma levels of soluble CD36, platelet activation, inflammation, and oxidative stress are increased in type 2 diabetic patients. Free Radic Biol Med. 2012 Apr 15;52(8):1318-24.
256. Koonen DP, Jensen MK, Handberg A. Soluble CD36-a marker of the (pathophysiological) role of CD36 in the metabolic syndrome? Arch Physiol Biochem. 2011 May;117(2):57-63.
257. Buqué X, Martínez MJ, Cano A, Miquilena-Colina ME, García-Monzón C, Aspichueta P, Ochoa B. A subset of dysregulated metabolic and survival genes is associated with severity of hepatic steatosis in obese Zucker rats. J Lipid Res. 2009 Mar;51(3):500-13.
258. Degrace P, Moindrot B, Mohamed I, Gresti J, Du ZY, Chardigny JM, Sébédio JL, Clouet P. Upregulation of liver VLDL receptor and FAT/ CD36 expression in LDLR-/-apoB100/100 mice fed trans-10,cis-12 conjugated linoleic acid. J Lipid Res. 2006 Dec;47(12):2647-55.
259. Inoue M, Ohtake T, Motomura W, Takahashi N, Hosoki Y, Miyoshi S, Suzuki Y, Saito H, Kohgo Y, Okumura T. Increased expression of PPARgamma in high fat diet-induced liver ste-atosis in mice. Biochem Biophys Res Commun. 2005 Oct 14;336(1):215-22.
260. Liu LF, Purushotham A, Wendel AA, Belury MA. Combined effects of rosiglitazone and conjugated linoleic acid on adiposity, insulin sensitivity, and hepatic steatosis in high-fat-fed mice. Am J Physiol Gastrointest Liver Physiol. 2007 Jun;292(6):G1671-82.
261. López-Parra M, Titos E, Horrillo R, Ferré N, González-Périz A, Martínez-Clemente M, Planagumà A, Masferrer J, Arroyo V, Clària J. Regulatory effects of arachidonate 5-lipoxygenase on hepatic microsomal TG transfer protein activity and VLDL-triglyceride and apoB secretion in obese mice. J Lipid Res. 2008 Dec;49(12):2513-23.
262. Bechmann LP, Gieseler RK, Sowa JP, Kahraman A, Erhard J, Wedemeyer I, Emons B, Jochum C, Feldkamp T, Gerken G, Canbay A. Apoptosis is associated with CD36/fatty acid translocase upregulation in non-alcoholic steatohepatitis. Liver Int. 2010 Jul;30(6):850-9.
263. Greco D, Kotronen A, Westerbacka J, Puig O, Arkkila P, Kiviluoto T, Laitinen S, Kolak M, Fisher RM, Hamsten A, Auvinen P, Yki-Järvinen H. Gene expression in human NAFLD. Am J Physiol Gastrointest Liver Physiol. 2008 May;294(5):G1281-7.
264. Gebe JA, Kiener PA, Ring HZ, Li X, Francke U, Aruffo A. Molecular cloning, mapping to human chromosome 1 q21-q23, and cell binding characteristics of Spalpha, a new member of the scavenger receptor cysteine-rich (SRCR) family of proteins. J Biol Chem. 1997 Mar 7;272(10):6151-8.
265. Gebe JA, Llewellyn M, Hoggatt H, Aruffo A. Molecular cloning, genomic organization and cell-binding characteristics of mouse Spalpha. Immunology. 2000 Jan;99(1):78-86.
266. Miyazaki T, Hirokami Y, Matsuhashi N, Takatsuka H, Naito M. Increased susceptibility of thy-mocytes to apoptosis in mice lacking AIM, a novel murine macrophage-derived soluble factor belonging to the scavenger receptor cysteine-rich domain superfamily. J Exp Med. 1999 Jan 18;189(2):413-22.
267. Kuwata K, Watanabe H, Jiang SY, Yamamoto T, Tomiyama-Miyaji C, Abo T, Miyazaki T, Naito M. AIM inhibits apoptosis of T cells and NKT cells in Corynebacterium-induced granuloma formation in mice. Am J Pathol. 2003 Mar;162(3):837-47.
268. Haruta I, Kato Y, Hashimoto E, Minjares C, Kennedy S, Uto H, Yamauchi K, Kobayashi M, Yusa S, Müller U, Hayashi N, Miyazaki T. Association of AIM, a novel apoptosis inhibitory factor, with hepatitis via supporting mac-rophage survival and enhancing phagocytotic function of macrophages. J Biol Chem. 2001 Jun 22;276(25):22910-4.
269. Arai S, Shelton JM, Chen M, Bradley MN, Castrillo A, Bookout AL, Mak PA, Edwards PA, Mangelsdorf DJ, Tontonoz P, Miyazaki T. A role for the apoptosis inhibitory factor AIM/Spalpha/ Api6 in atherosclerosis development. Cell Metab. 2005 Mar;1(3):201-13.
270. Valledor AF, Hsu LC, Ogawa S, Sawka-Verhelle D, Karin M, Glass CK. Activation of liver X receptors and retinoid X receptors prevents bacterial-induced macrophage apoptosis. Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17813-8.
271. Zou T GO, Berland R, Boyartchuk VL. Listeria monocytogenes infection induces prosurvival metabolic signaling in macrophages. Infect Immun. 2011 Apr;79(4):1526-35.
272. Joseph SB, Bradley MN, Castrillo A, Bruhn KW, Mak PA, Pei L, Hogenesch J, O'connell RM, Cheng G, Saez E, Miller JF, Tontonoz P. LXR-dependent gene expression is important for macrophage survival and the innate immune response. Cell. 2004 Oct 15;119(2):299-309.
273. Zhao C, Dahlman-Wright K. Liver X receptor in cholesterol metabolism J Endocrinol. [Review]. 2010;204(3):233-40.
274. Qu P, Du H, Li Y, Yan C. Myeloid-specific expression of Api6/AIM/Sp alpha induces systemic inflammation and adenocarcinoma in the lung. J Immunol. 2009 Feb 1;182(3):1648-59.
275. Li Y, Qu P, Wu L, Li B, Du H, Yan C. Api6/ AIM/Spa/CD5L overexpression in alveolar type II epithelial cells induces spontaneous lung adenocarcinoma. Cancer Res. 2011 Aug 15;71(16):5488-99.
276. Iwamura Y, Mori M, Nakashima K, Mikami T, Murayama K, Arai S, Miyazaki T. Apoptosis inhibitor of macrophage (AIM) diminishes lipid droplet-coating proteins leading to lipolysis in adipocytes. Biochem Biophys Res Commun. 2012 Jun 8;422(3):476-81.
277. Kurokawa J, Arai S, Nakashima K, Nagano H, Nishijima A, Miyata K, Ose R, Mori M, Kubota N, Kadowaki T, Oike Y, Koga H, Febbraio M, Iwanaga T, Miyazaki T. Macrophage-derived AIM is endocytosed into adipocytes and decreases lipid droplets via inhibition of fatty acid synthase activity. Cell Metab. 2010 Jun 9;11(6):479-92.
278. Kurokawa J, Nagano H, Ohara O, Kubota N, Kadowaki T, Arai S, Miyazaki T. Apoptosis inhibitor of macrophage (AIM) is required for obesity-associated recruitment of inflammatory macrophages into adipose tissue. Proc Natl Acad Sci U S A. 2011 Jul 19;108(29):12072-7.
279. Tissot JD, Sanchez JC, Vuadens F, Scherl A, Schifferli JA, Hochstrasser DF, Schneider P, Duchosal MA. IgM are associated to Sp alpha (CD5 antigen-like). Electrophoresis. 2002 Apr;23(7-8):1203-6.
280. Sarrias MR, Padilla O, Monreal Y, Carrascal M, Abian J, Vives J, Yélamos J, Lozano F. Biochemical characterization of recombinant and circulating human Spalpha. Tissue Antigens. 2004 Apr;63(4):335-44.
281. Sarrias MR, Roselló S, Sánchez-Barbero F, Sierra JM, Vila J, Yélamos J, Vives J, Casals C, Lozano F. A role for human Sp alpha as a pattern recognition receptor. J Biol Chem. 2005 Oct 21;280(42):35391-8.
282. Kim WK, Hwang HR, Kim do H, Lee PY, In YJ, Ryu HY, Park SG, Bae KH, Lee SC. Glycoproteomic analysis of plasma from patients with atopic dermatitis: CD5L and ApoE as potential biomarkers. Exp Mol Med. 2008 Dec 31;40(6):677-85.
283. Yu HR, Kuo HC, Sheen JM, Wang L, Lin IC, Wang CL, Yang KD. A unique plasma proteomic profiling with imbalanced fibrinogen cascade in patients with Kawasaki disease. Pediatr Allergy Immunol. 2009 Nov;20(7):699-707
284. Gangadharan B, Antrobus R, Dwek RA, Zitzmann N. Novel serum biomarker candidates for liver fibrosis in hepatitis C patients. Clin Chem. 2007 Oct;53(10):1792-9.
285. Gray J, Chattopadhyay D, Beale GS, Patman GL, Miele L, King BP, Stewart S, Hudson M, Day CP, Manas DM, Reeves HL. A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease. BMC Cancer. 2009;9:271-82.
286. Kim JW, Ye Q, Forgues M, Chen Y, Budhu A, Sime J, Hofseth LJ, Kaul R, Wang XW. Cancer-associated molecular signature in the tissue samples of patients with cirrhosis. Hepatology. 2004 Feb;39(2):518-27.
287. Ligtenberg AJ, Karlsson NG, Veerman EC. Deleted in malignant brain tumors-1 protein (DMBT1): a pattern recognition receptor with multiple binding sites. Int J Mol Sci. 2010;11(12):5212-33.
288. Takito J, Hikita C, Al-Awqati Q. Hensin, a new collecting duct protein involved in the in vitro plasticity of intercalated cell polarity. J Clin Invest. 1996 Nov 15;98(10):2324-31.
289. Li XJ, Snyder SH. Molecular cloning of Ebnerin, a von Ebner's gland protein associated with taste buds. J Biol Chem. 1995 Jul 28;270(30):17674-9.
290. Cheng H, Bjerknes M, Chen H. CRP-ductin: a gene expressed in intestinal crypts and in pancreatic and hepatic ducts. Anat Rec. 1996 Mar;244(3):327-43.
291. Holmskov U, Mollenhauer J, Madsen J, Vitved L, Gronlund J, Tornoe I, Kliem A, Reid KB, Poustka A, Skjodt K. Cloning of gp-340, a putative opsonin receptor for lung surfactant protein D. Proc Natl Acad Sci U S A. 1999 Sep 14;96(19):10794-9.
292. Ligtenberg AJ, Veerman EC, Nieuw Amerongen AV, Mollenhauer J. Salivary agglutinin/glycopro-tein-340/DMBT1: a single molecule with variable composition and with different functions in infection, inflammation and cancer. Biol Chem. 2007 Dec;388(12):1275-89.
293. Ericson T, Rundegren J. Characterization of a salivary agglutinin reacting with a serotype c strain of Streptococcus mutans. Eur J Biochem. 1983 Jun 15;133(2):255-61.
294. Nagashunmugam T, Malamud D, Davis C, Abrams WR, Friedman HM. Human subman-dibular saliva inhibits human immunodeficiency virus type 1 infection by displacing envelope glycoprotein gp120 from the virus. J Infect Dis. 1998 Dec;178(6):1635-41.
295. Prakobphol A, Xu F, Hoang VM, Larsson T, Bergstrom J, Johansson I, Frängsmyr L, Holmskov U, Leffler H, Nilsson C, Borén T, Wright JR, Strömberg N, Fisher SJ. Salivary agglutinin, which binds Streptococcus mutans and Helicobacter pylori, is the lung scavenger receptor cysteine-rich protein gp-340. J Biol Chem. 2000 Dec 22;275(51):39860-6.
296. Hartshorn KL, White MR, Mogues T, Ligtenberg T, Crouch E, Holmskov U. Lung and salivary scavenger receptor glycoprotein-340 contribute to the host defense against influenza A viruses. Am J Physiol Lung Cell Mol Physiol. 2003 Nov;285(5):L1066-76.
297. Bikker FJ, Ligtenberg AJ, Nazmi K, Veerman EC, van't Hof W, Bolscher JG, Poustka A, Nieuw Amerongen AV, Mollenhauer J. Identification of the bacteria-binding peptide domain on salivary agglutinin (gp-340/DMBT1), a member of the scavenger receptor cysteine-rich superfamily. J Biol Chem. 2002 Aug 30;277(35):32109-15.
298. Loimaranta V, Jakubovics NS, Hytonen J, Finne J, Jenkinson H F, Stromberg N. Fluid or surface-phase human salivary scavenger protein gp340 exposes different bacterial recognition properties. Infect Immun. 2005 Apr;73(4):2245-52.
299. Cannon G, Yi Y, Ni H, Stoddard E, Scales DA, Van Ryk DI, Chaiken I, Malamud D, Weissman D. HIV envelope binding by macrophage-expressed gp340 promotes HIV-1 infection. J Immunol. 2008 Aug 1;181(3):2065-70.
300. Stoddard E, Ni H, Cannon G, Zhou C, Kallenbach N, Malamud D, Weissman D. gp340 promotes transcytosis of human immunodeficiency virus type 1 in genital tract-derived cell lines and primary endocervical tissue. J Virol. 2009 Sep;83(17):8596-603.
301. Holmskov U, Lawson P, Teisner B, Tornoe I, Willis AC, Morgan C, Koch C, Reid KB. Isolation and characterization of a new member of the scavenger receptor superfamily, glycoprotein-340 (gp-340), as a lung surfactant protein-D binding molecule. J Biol Chem. 1997 May 23;272(21):13743-9.
302. Tino MJ, Wright JR. Glycoprotein-340 binds surfactant protein-A (SP-A) and stimulates alveolar macrophage migration in an SP-A-independent manner. Am J Respir Cell Mol Biol. 1999 Apr;20(4):759-68.
303. Rundegren J, Arnold RR. Differentiation and interaction of secretory immunoglobulin A and a calcium-dependent parotid agglutinin for several bacterial strains. Infect Immun. 1987 Feb;55(2):288-92.
304. Thim L, Mortz E. Isolation and characterization of putative trefoil peptide receptors. Regul Pept. 2000 Jun 30;90(1-3):61-8.
305. Thornton DJ, Davies JR, Kirkham S, Gautrey A, Khan N, Richardson PS, Sheehan JK. Identification of a nonmucin glycoprotein (gp-340) from a purified respiratory mucin preparation: evidence for an association involving the MUC5B mucin. Glycobiology. 2001 Nov;11(11):969-77.
306. Oho T, Bikker FJ, Nieuw Amerongen AV, Groenink J. A peptide domain of bovine milk lactoferrin inhibits the interaction between strep-tococcal surface protein antigen and a salivary agglutinin peptide domain. Infect Immun. 2004 Oct;72(10):6181-4.
307. Boackle RJ, Connor MH, Vesely J. High molecular weight non-immunoglobulin salivary agglutinins (NIA) bind C1Q globular heads and have the potential to activate the first complement component. Mol Immunol. 1993 Feb;30(3):309-19.
308. Reichhardt MP, Loimaranta V, Thiel S, Finne J, Meri S, Jarva H. The salivary scavenger and agglutinin binds MBL and regulates the lectin pathway of complement in solution and on surfaces. Front Immunol. 2012;3(205):1-10.
309. Leito J T, Ligtenberg AJ, van Houdt M, van den Berg TK, Wouters D. The bacteria binding glycoprotein salivary agglutinin (SAG/gp340) activates complement via the lectin pathway. Mol Immunol. 2011 Oct;49(1-2):185-90.
310. Takito J, Al-Awqati Q. Conversion of ES cells to columnar epithelia by hensin and to squa-mous epithelia by laminin. J Cell Biol. 2004 Sep 27;166(7):1093-102.
311. Al-Awqati Q. Terminal differentiation in epithelia: the role of integrins in hensin polymerization. Annu Rev Physiol. 2011;73:401-12.
312. Bisgaard HC, Holmskov U, Santoni-Rugiu E, Nagy P, Nielsen O, Ott P, Hage E, Dalhoff K, Rasmussen LJ, Tygstrup N. Heterogeneity of ductular reactions in adult rat and human liver revealed by novel expression of deleted in malignant brain tumor 1. Am J Pathol. 2002 Oct;161(4):1187-98.
313. Wu W, Kemp BL, Proctor ML, Gazdar AF, Minna JD, Hong WK, Mao L. Expression of DMBT1, a candidate tumor suppressor gene, is frequently lost in lung cancer. Cancer Res. 1999 Apr 15;59(8):1846-51.
314. Mollenhauer J, Wiemann S, Scheurlen W, Korn B, Hayashi Y, Wilgenbus KK, von Deimling A, Poustka A. DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumours. Nat Genet. 1997 Sep;17(1):32-9.
315. Braidotti P, Nuciforo PG, Mollenhauer J, Poustka A, Pellegrini C, Moro A, Bulfamante G, Coggi G, Bosari S, Pietra GG. DMBT1 expression is down-regulated in breast cancer. BMC Cancer. 2004 Aug 9;4:46-55.
316. Du J, Guan M, Fan J, Jiang H. Loss of DMBT1 expression in human prostate cancer and its correlation with clinical progressive features. Urology. 2010 Feb;77(2):509.e9-13.
317. Mollenhauer J, Deichmann M, Helmke B, Müller H, Kollender G, Holmskov U, Ligtenberg T, Krebs I, Wiemann S, Bantel-Schaal U, Madsen J, Bikker F, Klauck SM, Otto HF, Moldenhauer G, Poustka A. Frequent downregulation of DMBT1 and galectin-3 in epithelial skin cancer. Int J Cancer. 2003 Jun 10;105(2):149-57.
318. Mollenhauer J, Müller H, Kollender G, Lyer S, Diedrichs L, Helmke B, Holmskov U, Ligtenberg T, Herbertz S, Krebs I, Madsen J, Bikker F, Schmitt L, Wiemann S, Scheurlen W, Otto HF, von Deimling A, Poustka A. Sequential changes of the DMBT1 expression and location in normal lung tissue and lung carcinomas. Genes Chromosomes Cancer. 2002 Oct;35(2):164-9.
319. Mori M, Shiraishi T, Tanaka S, Yamagata M, Mafune K, Tanaka Y, Ueo H, Barnard GF, Sugimachi K. Lack of DMBT1 expression in oesophageal, gastric and colon cancers. Br J Cancer. 1999 Jan;79(2):211-3.
320. Conde AR, Martins AP, Brito M, Manuel A, Ramos S, Malta-Vacas J, Renner M, Poustka A, Mollenhauer J, Monteiro C. DMBT1 is frequently downregulated in well-differentiated gastric carcinoma but more frequently upregulated across various gastric cancer types. Int J Oncol. 2007 Jun;30(6):1441-6.
321. Mollenhauer J, Herbertz S, Helmke B, Kollender G, Krebs I, Madsen J, Holmskov U, Sorger K, Schmitt L, Wiemann S, Otto HF, Gröne HJ, Poustka A. Deleted in malignant brain tumors 1 is a versatile mucin-like molecule likely to play a differential role in digestive tract cancer. Cancer Res. 2001 Dec 15;61(24):8880-6.
322. Deng H, Gao YB, Wang HF, Jin XL, Xiao JC. Expression of deleted in malignant brain tumours 1 (DMBT1) relates to the proliferation and malignant transformation of hepatic progenitor cells in hepatitis B virus-related liver diseases. Histopathology. 2012 Jan;60(2):249-60.
323. Frau M, Simile MM, Tomasi ML, Demartis MI, Daino L, Seddaiu MA, Brozzetti S, Feo CF, Massarelli G, Solinas G, Feo F, Lee JS, Pascale RM. An expression signature of phenotypic resistance to hepatocellular carcinoma identified by cross-species gene expression analysis. Cell Oncol (Dordr). 2012 Jun;35(3):163-73.
324. Huang J, Zheng DL, Qin FS, Cheng N, Chen H, Wan BB, Wang YP, Xiao HS, Han ZG. Genetic and epigenetic silencing of SCARA5 may contribute to human hepatocellular carcinoma by activating FAK signaling. J Clin Invest. 2010 Jan;120(1):223-41.
325. Jiang Y, Oliver P, Davies KE, Platt N. Identification and characterization of murine SCARA5, a novel class A scavenger receptor that is expressed by populations of epithelial cells. J Biol Chem. 2006 Apr 28;281(17):11834-45.
326. Li JY, Paragas N, Ned RM, Qiu A, Viltard M, Leete T, Drexler IR, Chen X, Sanna-Cherchi S, Mohammed F, Williams D, Lin CS, Schmidt-Ott KM, Andrews NC, Barasch J. Scara5 is a ferritin receptor mediating non-transferrin iron delivery. Dev Cell. 2009 Jan;16(1):35-46.
327. Geninatti Crich S, Cutrin JC, Lanzardo S, Conti L, Kálmán FK, Szabó I, Lago NR, Iolascon A, Aime S. Mn-loaded apoferritin: a highly sensitive MRI imaging probe for the detection and characterization of hepatocarcinoma lesions in a transgenic mouse model. Contrast Media Mol Imaging. May-Jun;7(3):281-8.
328. Yan N, Zhang S, Yang Y, Cheng L, Li C, Dai L, Dai L, Zhang X, Fan P, Tian H, Wang R, Chen X, Su X, Li Y, Zhang J, Du T, Wei Y, Deng H. Therapeutic upregulation of Class A scavenger receptor member 5 inhibits tumor growth and metastasis. Cancer Sci. 2012 Sep;103(9):1631-9.
329. Khamas A, Ishikawa T, Shimokawa K, Mogushi K, Iida S, Ishiguro M, Mizushima H, Tanaka H, Uetake H, Sugihara K. Screening for epige-netically masked genes in colorectal cancer Using 5-Aza-2'-deoxycytidine, microarray and gene expression profile. Cancer Genomics Proteomics. 2012 Mar-Apr;9(2):67-75.
330. Hoekstra M, Out R, Kruijt JK, Van Eck M, Van Berkel TJ. Diet induced regulation of genes involved in cholesterol metabolism in rat liver parenchymal and Kupffer cells. J Hepatol. 2005 Mar;42(3):400-7.
331. Goldberger G, Bruns GA, Rits M, Edge MD, Kwiatkowski DJ. Human complement factor I: analysis of cDNA-derived primary structure and assignment of its gene to chromosome 4. J Biol Chem. 1987 Jul 25;262(21):10065-71.
332. Schlaf G, Rothermel E, Oppermann M, Schieferdecker HL, Jungermann K, Gotze O. Rat complement factor I: molecular cloning, sequencing and expression in tissues and isolated cells. Immunology. 1999 Nov;98(3):464-74.
333. Leytus SP, Loeb KR, Hagen FS, Kurachi K, Davie EW. A novel trypsin-like serine protease (hepsin) with a putative transmembrane domain expressed by human liver and hepatoma cells. Biochemistry. 1988 Feb 9;27(3):1067-74.
334. Lin ZY, Chuang YH, Chuang WL. Cancer-associated fibroblasts up-regulate CCL2, CCL26, IL6 and LOXL2 genes related to promotion of cancer progression in hepatocellular carcinoma cells. Biomed Pharmacother. 2012 Oct;66(7):525-9.
335. Chen R, Tan Y, Wang M, Wang F, Yao Z, Dong L, Ye M, Wang H, Zou H. Development of glycoprotein capture-based label-free method for the high-throughput screening of differential glycoproteins in hepatocellular carcinoma. Mol Cell Proteomics. 2011 Jul;10(7):1-13.
336. Wisse E, Braet F, Luo D, De Zanger R, Jans D, Crabbé E, Vermoesen A. Structure and function of sinusoidal lining cells in the liver. Toxicol Pathol. 1996 Jan-Feb;24(1):100-11.
337. Nakagawa-Toyama Y, Hirano K, Tsujii K, Nishida M, Miyagawa J, Sakai N, Yamashita S. Human scavenger receptor class B type I is expressed with cell-specific fashion in both initial and terminal site of reverse cholesterol transport. Atherosclerosis. 2005;183(1):75-83.
338. Malerod L, Juvet K, Gjoen T, Berg T. The expression of scavenger receptor class B, type I (SR-BI) and caveolin-1 in parenchymal and nonparenchymal liver cells. Cell Tissue Res. 2002 Feb;307(2):173-80.
339. Tomokiyo Ri, Jinnouchi K, Honda M, Wada Y, Hanada N, Hiraoka T, Suzuki H, Kodama T, Takahashi K, Takeya M. Production, characterization, and interspecies reactivities of monoclonal antibodies against human class A macrophage scavenger receptors. Atherosclerosis. 2002 Mar;161(1):123-32.
340. van der Laan LJ, Döpp EA, Haworth R, Pikkarainen T, Kangas M, Elomaa O, Dijkstra CD, Gordon S, Tryggvason K, Kraal G. Regulation and functional involvement of macrophage scavenger receptor MARCO in clearance of bacteria in vivo. J Immunol. 1999 Jan 15;162(2):939-47.
341. Devey L, Ferenbach D, Mohr E, Sangster K, Bellamy CO, Hughes J, Wigmore SJ. Tissue-resident macrophages protect the liver from ischemia reperfusion injury via a heme oxygen-ase-1-dependent mechanism. Mol Ther. 2009 Jan;17(1):65-72.
342. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008 Jan;88(1):125-72.
343. Strazzabosco M, Spirli C, Okolicsanyi L. Pathophysiology of the intrahepatic biliary epithelium. J Gastroenterol Hepatol. 2000 Mar;15(3):244-53.
344. Gao B, Radaeva S, Park O. Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. J Leukoc Biol. 2009 Sep;86(3):513-28.
345. Sumpter TL, Abe M, Tokita D, Thomson AW. Dendritic cells, the liver, and transplantation. Hepatology. 2007 Dec;46(6):2021-31.
346. Moeller JB, Nielsen MJ, Reichhardt MP, Schlosser A, Sorensen GL, Nielsen O, Tornøe I, Grønlund J, Nielsen ME, Jørgensen JS, Jensen ON, Mollenhauer J, Moestrup SK, Holmskov U. CD163-L1 is an endocytic macrophage protein strongly regulated by mediators in the inflammatory response. J Immunol. 2012 Mar 1;188(5):2399-409.
347. Harshyne LA, Zimmer MI, Watkins SC, Barratt-Boyes SM. A role for class A scavenger receptor in dendritic cell nibbling from live cells. J Immunol. 2003 Mar 1;170(5):2302-9.
348. Parlato S, Romagnoli G, Spadaro F, Canini I, Sirabella P, Borghi P, Ramoni C, Filesi I, Biocca S, Gabriele L, Belardelli F. LOX-1 as a natural IFN-alpha-mediated signal for apoptotic cell uptake and antigen presentation in dendritic cells. Blood. 2010 Feb 25;115(8):1554-63.
349. Walker ID, Glew MD, O'Keeffe MA, Metcalfe SA, Clevers HC, Wijngaard PL, Adams TE, Hein WR. A novel multi-gene family of sheep gamma delta T cells. Immunology. 1994 Dec;83(4):517-23.
350. Jacquinet E, Rao NV, Rao GV, Zhengming W, Albertine KH, Hoidal JR. Cloning and characterization of the cDNA and gene for human epitheliasin. Eur J Biochem. 2001 May;268(9):2687-99.
351. Handberg A, Norberg M, Stenlund H, Hallmans G, Attermann J, Eriksson JW. Soluble CD36 (sCD36) clusters with markers of insulin resistance, and high sCD36 is associated with increased type 2 diabetes risk. J Clin Endocrinol Metab. 2010 Apr;95(4):1939-46.